IP Library Granted Patent US 9,457,013
Granted Patent B2
US 9,457,013 · App. 14/276,104 · Granted Oct 4, 2016

Method for treating a neurological disorder associated with hypoxia using a small moleucule MIF inhibitor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,457,013
App. No.
14/276,104
Granted
Oct 4, 2016
Kind
B2
Abstract

Methods are provided for treating pathologies associated with hypoxia with an MIF inhibitor. Methods are also provided for treating a subject having, or at risk for pulmonary hypertension, with an MIF inhibitor. Methods are also provided for reating a subject having, or at risk from, a CNS disorder associated with hypoxia, with an MIF inhibitor. Methods are also provided of treating severe chronic lung disease, hypoxia-induced right ventricular hypertrophy or hypoxia-induced pulmonary vascular remodeling with an MIF inhibitor. Methods of diagnosing a subject with pulmonary hypertension are also provided.

Claims (12)

1. A method for treating a neurological disorder associated with hypoxia, or a mental disorder associated with hypoxia, in a subject comprising administering to the subject an amount of a small molecule macrophage migration inhibitory factor (MIF) inhibitor effective to treat the neurological or mental disorder.

2. The method of claim 1 , wherein the disorder associated with hypoxia is mental.

3. The method of claim 1 , wherein the disorder associated with hypoxia is neurological.

4. The method of claim 1 , wherein the disorder is a cognitive dysfunction.

5. The method of claim 1 , wherein the disorder is anxiety.

6. The method of claim 1 , wherein the disorder is depression.

7. The method of claim 1 , wherein the disorder is memory deficit.

8. The method of claim 1 , wherein the MIF inhibitor is administered so as to cross the blood brain barrier of the subject.

9. The method of claim 1 , wherein the MIF inhibitor is administered inhalationally.

10. The method of claim 1 , wherein the MIF inhibitor is administered orally.

11. The method of claim 1 , wherein the MIF inhibitor is administered intravenously.

12. The method of claim 1 , wherein the MIF inhibitor has the structure:

Assignments (1)
CHANGE OF NAME Recorded Aug 20, 2019
From: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
To: THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Reel/Frame 050102/0485 →